Liraglutide studies: 1,219 papers with results
Page 16 of 25
- Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes.
Iwao T · Journal of diabetes and its complications · 2013
Observational study · 7 results
- Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide.
Haraguchi A · Minerva endocrinologica · 2014
Observational study · 3 results
- Effectiveness of liraglutide in the treatment of adolescent obesity.
Ruiz Pons M · Anales de pediatria · 2025
Observational study · 9 results
- Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease.
Liu Y · Lipids in health and disease · 2017
Observational study · 2 results
- Comparing Quality of Life in Type 2 Diabetic Patients Using Dulaglutide and Liraglutide
Ghosh A · Journal of the Endocrine Society · 2021
Observational study · 2 results
- Marked weight loss on liraglutide 3.0 mg: Real-life experience of a Swiss cohort with obesity.
Santini S · Obesity (Silver Spring, Md.) · 2023
Observational study · 8 results
- Combining GLP-1 Receptor Agonists and Health-Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real-World Single-Center Study.
Lischka J · Pediatric obesity · 2026
Observational study · 9 results
- Efficacy and safety profile of Glucagon-Like Peptide-1 Receptor Agonist in obese Type-2 diabetes patients from a private institution in Karachi.
Qasim SF · Pakistan journal of medical sciences · 2023
Observational study · 16 results
- Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activation in Patients With Diabetes.
Ikonomidis I · Journal of the American Heart Association · 2025
Observational study · 17 results
- Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study.
Jensen AB · BMC endocrine disorders · 2025
Observational study · 12 results
- Liraglutide and not lifestyle intervention reduces soluble CD163 after comparable weight loss in obese participants with prediabetes or type 2 diabetes mellitus.
Grannes H · Cardiovascular diabetology · 2024
Observational study · 4 results
- Effects of Treatment with Liraglutide Early after Surgical Intervention on Clinical Outcomes in Patients with Short Bowel Syndrome: A Pilot Observational "Real-Life" Study.
Merlo FD · Nutrients · 2023
Observational study · 8 results
- Improved diastolic function in type 2 diabetes after a six month liraglutide treatment.
Saponaro F · Diabetes research and clinical practice · 2016
Observational study · 6 results
- Is liraglutide safe and effective in the elderly obese patients?: A single center experience.
Oral A · Medicine · 2025
Observational study · 8 results
- Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.
Li CJ · Cardiovascular diabetology · 2014
Observational study · 10 results
- Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation.
Cotugno M · Acta diabetologica · 2015
Observational study · 4 results
- Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
Giagulli VA · Andrology · 2015
Observational study · 5 results
- Long-term weight outcomes in patients treated with liraglutide 3.0 mg in real-world clinical practice.
Grannell A · Clinical obesity · 2024
Observational study · 4 results
- Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus.
Du J · Frontiers in endocrinology · 2022
Observational study · 6 results
- Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
García Díaz E · Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion · 2016
Observational study · 1 result
- Microvascular Density and Circulating Endothelial Progenitor Cells Before and After Treatment with Incretin Mimetics in Diabetic Patients.
De Ciuceis C · High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2018
Observational study · 3 results
- Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
Kuwata H · Journal of diabetes investigation · 2021
Observational study · 12 results
- Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy.
Nakatani Y · Diabetes & metabolism · 2017
Observational study · 6 results
- Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
Fujioka K · Obesity (Silver Spring, Md.) · 2016
Observational study · 9 results
- Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
Alatorre C · Diabetes, obesity & metabolism · 2017
Observational study · 8 results
- A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs.
Funch D · Diabetes, obesity & metabolism · 2014
Observational study · 2 results
- Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.
Uzoigwe C · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021
Observational study · 15 results
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®).
McIntyre RS · Journal of affective disorders · 2025
Observational study · 13 results
- Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.
Lingvay I · BMJ open diabetes research & care · 2020
Observational study · 7 results
- Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events.
He L · Frontiers in pharmacology · 2024
Observational study · 17 results
- Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes.
Lee WC · Diabetes, obesity & metabolism · 2014
Observational study · 4 results
- Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis.
Guo H · Frontiers in pharmacology · 2024
Observational study · 12 results
- Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study.
Nakhla M · Cardiovascular drugs and therapy · 2025
Observational study · 20 results
- Genetic and physiological insights into satiation variability predict responses to obesity treatment.
Cifuentes L · Cell metabolism · 2025
Observational study · 2 results
- Semaglutide versus other GLP-1 receptor agonists in patients with MASLD.
Kuo CC · Hepatology communications · 2025
Observational study · 10 results
- Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study.
Ghosal S · Clinical diabetes and endocrinology · 2018
Observational study · 10 results
- Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
Pelletier EM · Journal of medical economics · 2012
Observational study · 7 results
- The impact of approved anti-obesity medications on osteoarthritis.
Baser O · Expert opinion on pharmacotherapy · 2024
Observational study · 7 results
- Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.
Shirani A · Therapeutic advances in neurological disorders · 2024
Observational study · 3 results
- Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight/obesity patients with type 2 diabetes mellitus.
Dai C · Medicine · 2022
Observational study · 4 results
- Otolaryngologic Side Effects of GLP-1 Receptor Agonists.
Khan FI · The Laryngoscope · 2025
Observational study · 20 results
- Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain.
Gomez-Peralta F · Diabetic medicine : a journal of the British Diabetic Association · 2018
Observational study · 12 results
- Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk.
Huang WC · Scientific reports · 2021
Observational study · 9 results
- The Use of Decomposition Methods in Real-World Treatment Benefits Evaluation for Patients with Type 2 Diabetes Initiating Different Injectable Therapies: Findings from the INITIATOR Study.
Brekke L · Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2017
Observational study · 6 results
- GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events.
Pak KY · Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2025
Observational study · 36 results
- Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study.
Chen SY · European heart journal. Cardiovascular pharmacotherapy · 2025
Observational study · 28 results
- A case for screening real-world data for collateral drug benefits: Glucagon-like peptide 1 receptor agonists and bile acid diarrhea.
Rahbek MT · Pharmacoepidemiology and drug safety · 2024
Observational study · 6 results
- One-year usage patterns of SGLT-2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes in a real-world population.
Donnelly LA · Diabetes, obesity & metabolism · 2026
Observational study · 14 results
- The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
Boye KS · Diabetes, obesity & metabolism · 2023
Observational study · 7 results
- Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM: A Multicenter Real-World Study.
Xie Z · Obesity (Silver Spring, Md.) · 2026
Observational study · 11 results